Does the media favor NKTR or MDXG?

In the previous week, MiMedx Group had 7 more articles in the media than Nektar Therapeutics. MarketBeat recorded 8 mentions for MiMedx Group and 1 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 1.17 beat MiMedx Group's score of 0.32 indicating that Nektar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiMedx Group 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AMLX or MDXG?

In the previous week, Amylyx Pharmaceuticals had 4 more articles in the media than MiMedx Group. MarketBeat recorded 12 mentions for Amylyx Pharmaceuticals and 8 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.32 beat Amylyx Pharmaceuticals' score of 0.04 indicating that MiMedx Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MiMedx Group 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, MDXG or PGEN?

MiMedx Group has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiMedx Group $418.63M 1.51 $48.58M $0.04 108.50 Precigen $85.72M 30.07 -$250.64M -$1.04 N/A

Is MDXG or PGEN more profitable?

MiMedx Group has a net margin of 1.76% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat MiMedx Group's return on equity. Company Net Margins Return on Equity Return on Assets MiMedx Group 1.76% 12.09% 9.22% Precigen -183.98% 423.75% 84.39%

Does the media refer more to MDXG or PGEN?

In the previous week, Precigen had 32 more articles in the media than MiMedx Group. MarketBeat recorded 40 mentions for Precigen and 8 mentions for MiMedx Group. Precigen's average media sentiment score of 0.80 beat MiMedx Group's score of 0.32 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Precigen 14 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, MDXG or VCEL?

MiMedx Group has higher revenue and earnings than Vericel. Vericel is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiMedx Group $418.63M 1.51 $48.58M $0.04 108.50 Vericel $276.26M 8.36 $16.52M $0.47 95.94

Is MDXG or VCEL more profitable?

Vericel has a net margin of 7.91% compared to MiMedx Group's net margin of 1.76%. MiMedx Group's return on equity of 12.09% beat Vericel's return on equity. Company Net Margins Return on Equity Return on Assets MiMedx Group 1.76% 12.09% 9.22% Vericel 7.91% 6.91% 5.02%

Does the media refer more to MDXG or VCEL?

In the previous week, Vericel had 14 more articles in the media than MiMedx Group. MarketBeat recorded 22 mentions for Vericel and 8 mentions for MiMedx Group. Vericel's average media sentiment score of 0.55 beat MiMedx Group's score of 0.32 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Vericel 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MDXG or SION?

In the previous week, MiMedx Group had 3 more articles in the media than Sionna Therapeutics. MarketBeat recorded 8 mentions for MiMedx Group and 5 mentions for Sionna Therapeutics. MiMedx Group's average media sentiment score of 0.32 beat Sionna Therapeutics' score of 0.17 indicating that MiMedx Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Sionna Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

MiMedx Group (MDXG) Competitors

$4.34 +0.16 (+3.83%)

Closing price 04:00 PM Eastern

Extended Trading

$4.34 0.00 (-0.12%)

As of 07:34 PM Eastern

Compare

MDXG vs. NKTR, AMLX, PGEN, VCEL, and SION

Should you buy MiMedx Group stock or one of its competitors? MarketBeat compares MiMedx Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MiMedx Group include Nektar Therapeutics (NKTR), Amylyx Pharmaceuticals (AMLX), Precigen (PGEN), Vericel (VCEL), and Sionna Therapeutics (SION). These companies are all part of the "biotechnology" industry.

How does MiMedx Group compare to Nektar Therapeutics?

Nektar Therapeutics (NASDAQ:NKTR) and MiMedx Group (NASDAQ:MDXG) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Nektar Therapeutics has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 2.5% of Nektar Therapeutics shares are held by company insiders. Comparatively, 2.5% of MiMedx Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, MiMedx Group had 7 more articles in the media than Nektar Therapeutics. MarketBeat recorded 8 mentions for MiMedx Group and 1 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 1.17 beat MiMedx Group's score of 0.32 indicating that Nektar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nektar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiMedx Group	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiMedx Group has a net margin of 1.76% compared to Nektar Therapeutics' net margin of -284.18%. MiMedx Group's return on equity of 12.09% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-284.18%	-85.40%	-39.99%
MiMedx Group	1.76%	12.09%	9.22%

Nektar Therapeutics currently has a consensus price target of $150.00, suggesting a potential upside of 96.13%. MiMedx Group has a consensus price target of $8.50, suggesting a potential upside of 95.85%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Nektar Therapeutics is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

MiMedx Group has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	46.79	-$164.08M	-$8.42	N/A
MiMedx Group	$418.63M	1.51	$48.58M	$0.04	108.50

Summary

MiMedx Group beats Nektar Therapeutics on 10 of the 15 factors compared between the two stocks.

How does MiMedx Group compare to Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and MiMedx Group (NASDAQ:MDXG) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 2.5% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Amylyx Pharmaceuticals has a beta of -0.21, suggesting that its share price is 121% less volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

MiMedx Group has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	29.04	-$144.74M	-$1.50	N/A
MiMedx Group	$418.63M	1.51	$48.58M	$0.04	108.50

In the previous week, Amylyx Pharmaceuticals had 4 more articles in the media than MiMedx Group. MarketBeat recorded 12 mentions for Amylyx Pharmaceuticals and 8 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.32 beat Amylyx Pharmaceuticals' score of 0.04 indicating that MiMedx Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiMedx Group	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiMedx Group has a net margin of 1.76% compared to Amylyx Pharmaceuticals' net margin of 0.00%. MiMedx Group's return on equity of 12.09% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
MiMedx Group	1.76%	12.09%	9.22%

Amylyx Pharmaceuticals currently has a consensus target price of $25.38, suggesting a potential upside of 11.20%. MiMedx Group has a consensus target price of $8.50, suggesting a potential upside of 95.85%. Given MiMedx Group's higher possible upside, analysts clearly believe MiMedx Group is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

MiMedx Group beats Amylyx Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does MiMedx Group compare to Precigen?

MiMedx Group (NASDAQ:MDXG) and Precigen (NASDAQ:PGEN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

MiMedx Group has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.51	$48.58M	$0.04	108.50
Precigen	$85.72M	30.07	-$250.64M	-$1.04	N/A

MiMedx Group currently has a consensus target price of $8.50, indicating a potential upside of 95.85%. Precigen has a consensus target price of $14.50, indicating a potential upside of 100.55%. Given Precigen's higher possible upside, analysts plainly believe Precigen is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Precigen	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

MiMedx Group has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, Precigen has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market.

In the previous week, Precigen had 32 more articles in the media than MiMedx Group. MarketBeat recorded 40 mentions for Precigen and 8 mentions for MiMedx Group. Precigen's average media sentiment score of 0.80 beat MiMedx Group's score of 0.32 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precigen	14 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by insiders. Comparatively, 41.4% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

MiMedx Group has a net margin of 1.76% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat MiMedx Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	1.76%	12.09%	9.22%
Precigen	-183.98%	423.75%	84.39%

Summary

MiMedx Group beats Precigen on 9 of the 17 factors compared between the two stocks.

How does MiMedx Group compare to Vericel?

MiMedx Group (NASDAQ:MDXG) and Vericel (NASDAQ:VCEL) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

MiMedx Group presently has a consensus price target of $8.50, indicating a potential upside of 95.85%. Vericel has a consensus price target of $58.40, indicating a potential upside of 29.52%. Given MiMedx Group's stronger consensus rating and higher probable upside, analysts clearly believe MiMedx Group is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Vericel	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

MiMedx Group has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, Vericel has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

MiMedx Group has higher revenue and earnings than Vericel. Vericel is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.51	$48.58M	$0.04	108.50
Vericel	$276.26M	8.36	$16.52M	$0.47	95.94

79.2% of MiMedx Group shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by company insiders. Comparatively, 7.6% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Vericel had 14 more articles in the media than MiMedx Group. MarketBeat recorded 22 mentions for Vericel and 8 mentions for MiMedx Group. Vericel's average media sentiment score of 0.55 beat MiMedx Group's score of 0.32 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vericel	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vericel has a net margin of 7.91% compared to MiMedx Group's net margin of 1.76%. MiMedx Group's return on equity of 12.09% beat Vericel's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	1.76%	12.09%	9.22%
Vericel	7.91%	6.91%	5.02%

Summary

MiMedx Group beats Vericel on 10 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to Sionna Therapeutics?

MiMedx Group (NASDAQ:MDXG) and Sionna Therapeutics (NASDAQ:SION) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

MiMedx Group has a net margin of 1.76% compared to Sionna Therapeutics' net margin of 0.00%. MiMedx Group's return on equity of 12.09% beat Sionna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	1.76%	12.09%	9.22%
Sionna Therapeutics	N/A	-27.31%	-25.88%

79.2% of MiMedx Group shares are held by institutional investors. 2.5% of MiMedx Group shares are held by insiders. Comparatively, 5.1% of Sionna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

MiMedx Group has higher revenue and earnings than Sionna Therapeutics. Sionna Therapeutics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.51	$48.58M	$0.04	108.50
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A

MiMedx Group has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market.

MiMedx Group presently has a consensus target price of $8.50, indicating a potential upside of 95.85%. Sionna Therapeutics has a consensus target price of $55.00, indicating a potential upside of 7.76%. Given MiMedx Group's higher probable upside, analysts clearly believe MiMedx Group is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Sionna Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85

In the previous week, MiMedx Group had 3 more articles in the media than Sionna Therapeutics. MarketBeat recorded 8 mentions for MiMedx Group and 5 mentions for Sionna Therapeutics. MiMedx Group's average media sentiment score of 0.32 beat Sionna Therapeutics' score of 0.17 indicating that MiMedx Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sionna Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

MiMedx Group beats Sionna Therapeutics on 12 of the 16 factors compared between the two stocks.

Get MiMedx Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDXG vs. The Competition

Export

Metric	MiMedx Group	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$632.60M	$3.66B	$6.98B	$12.99B
Dividend Yield	N/A	3.76%	2.59%	9.93%
P/E Ratio	108.53	8.44	270.86	26.03
Price / Sales	1.51	1,275.27	662.50	111.63
Price / Cash	7.51	101.37	71.89	50.37
Price / Book	2.93	18.09	13.24	6.24
Net Income	$48.58M	-$13.22M	$3.45B	$342.57M
7 Day Performance	5.08%	6.22%	4.66%	4.33%
1 Month Performance	3.33%	-3.31%	-1.56%	-1.02%
1 Year Performance	-38.96%	59.15%	77.45%	22.54%

MiMedx Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDXG MiMedx Group	2.9859 of 5 stars	$4.34 +3.8%	$8.50 +95.9%	-42.3%	$632.60M	$418.63M	108.53	870
NKTR Nektar Therapeutics	2.7973 of 5 stars	$72.87 +3.2%	$150.00 +105.8%	+227.2%	$2.46B	$55.23M	N/A	220	Positive News Upcoming Earnings
AMLX Amylyx Pharmaceuticals	2.7804 of 5 stars	$22.12 +9.7%	$25.38 +14.7%	+195.4%	$2.46B	$87.37M	N/A	200	News Coverage Earnings Report Analyst Forecast
PGEN Precigen	3.8107 of 5 stars	$6.69 +1.1%	$12.50 +87.0%	+277.6%	$2.39B	$31.60M	N/A	190	Trending News Earnings Report Analyst Upgrade Insider Trade Analyst Revision Gap Up
VCEL Vericel	4.136 of 5 stars	$46.05 flat	$58.40 +26.8%	+23.3%	$2.36B	$276.26M	97.91	300	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDXG) was last updated on 8/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiMedx Group (MDXG) Competitors

MDXG vs. NKTR, AMLX, PGEN, VCEL, and SION

How does MiMedx Group compare to Nektar Therapeutics?

Summary

How does MiMedx Group compare to Amylyx Pharmaceuticals?

Summary

How does MiMedx Group compare to Precigen?

Summary

How does MiMedx Group compare to Vericel?

Summary

How does MiMedx Group compare to Sionna Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG vs. The Competition

MiMedx Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiMedx Group (MDXG) Competitors

MDXG vs. NKTR, AMLX, PGEN, VCEL, and SION

How does MiMedx Group compare to Nektar Therapeutics?

Which has more volatility & risk, NKTR or MDXG?

Do insiders & institutionals hold more shares of NKTR or MDXG?

Does the media favor NKTR or MDXG?

Is NKTR or MDXG more profitable?

Do analysts prefer NKTR or MDXG?

Which has stronger earnings and valuation, NKTR or MDXG?

Summary

How does MiMedx Group compare to Amylyx Pharmaceuticals?

Do insiders and institutionals hold more shares of AMLX or MDXG?

Which has more volatility & risk, AMLX or MDXG?

Which has stronger valuation & earnings, AMLX or MDXG?

Does the media favor AMLX or MDXG?

Is AMLX or MDXG more profitable?

Do analysts rate AMLX or MDXG?

Summary

How does MiMedx Group compare to Precigen?

Which has preferable valuation and earnings, MDXG or PGEN?

Do analysts prefer MDXG or PGEN?

Which has more volatility & risk, MDXG or PGEN?

Does the media refer more to MDXG or PGEN?

Do insiders & institutionals have more ownership in MDXG or PGEN?

Is MDXG or PGEN more profitable?

Summary

How does MiMedx Group compare to Vericel?

Do analysts prefer MDXG or VCEL?

Which has more risk and volatility, MDXG or VCEL?

Which has stronger earnings & valuation, MDXG or VCEL?

Do insiders and institutionals have more ownership in MDXG or VCEL?

Does the media refer more to MDXG or VCEL?

Is MDXG or VCEL more profitable?

Summary

How does MiMedx Group compare to Sionna Therapeutics?

Is MDXG or SION more profitable?

Do institutionals & insiders have more ownership in MDXG or SION?

Which has stronger valuation and earnings, MDXG or SION?

Which has more risk and volatility, MDXG or SION?

Do analysts recommend MDXG or SION?

Does the media favor MDXG or SION?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG vs. The Competition

MiMedx Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools